IMMvention Therapeutix, Inc.

IMMvention Therapeutix, Inc is a US-based biotechnology company specializing in the discovery and development of novel small molecule inhibitors targeting Bach1, a key transcription factor.

We are focused on creating transformative therapies for patients suffering from a range of debilitating diseases, including sickle cell disease (SCD), renal diseases, cardiometabolic diseases, and neurodegenerative diseases. Our research and development efforts are centered around oral medications, offering a more accessible treatment option for patients globally.

IMMvention Therapeutix is a venture-funded company dedicated to advancing innovative treatments and improving patient outcomes. We leverage cutting-edge research in molecular biology to address unmet medical needs and bring impactful therapies to market. Our team combines deep scientific expertise with a commitment to patient-centric drug development.

Founded in 2017 and currently employing 13 individuals, IMMvention Therapeutix is rapidly progressing its pipeline of potential therapies, demonstrating significant promise in addressing complex diseases.